Compare Cardinal Health Inc (CAH) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Synopsys, Inc. — how do they compare? Cardinal Health Inc trades at $240 (market cap $55.88B), while Synopsys, Inc. trades at $411.99 (market cap $78.68B). The key difference: Synopsys, Inc. is the larger of the two by market cap, and Cardinal Health Inc pays a 0.86% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| CAH | SNPS | |
|---|---|---|
Market Cap | $55.88B | $78.68B |
Sector | Health | Technology |
52-Week High | $240.26 | $625.80 |
52-Week Low | $146.04 | $372.33 |
Enterprise Value | $59.91B | $87.04B |
Dividend Yield | 0.86% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
